Closing the gap: How statins have narrowed the heart risk divide between obese and slim adults

How do statins reduce heart risk? Recent medical evidence reveals a dramatic shift in how we view the relationship between body weight and cardiovascular health. While carrying excess weight has historically been linked to higher rates of heart attack and stroke, widespread cholesterol-lowering therapies have profoundly altered this narrative. New data shows that modern preventive medicine is effectively closing the health divide, offering powerful protection to individuals who face elevated risks due to their weight.

I’m sure you’ve heard of statins – perhaps you’re taking one yourself. A study recently published in The Lancet described statins as a “significant public health story,” and we don’t often hear that. It’s an accolade they have certainly earned.

For decades, obesity has been recognised as one of the strongest predictors of cardiovascular disease. Excess body fat is associated with high cholesterol, raised blood pressure, insulin resistance, chronic inflammation and type 2 diabetes, all of which increase the risk of heart attacks and strokes. Public health advice has therefore consistently encouraged weight loss as a key strategy for reducing cardiovascular risk – easy to recommend, much harder to achieve.

However, recent research suggests that one important aspect of this relationship has changed. Thanks largely to the widespread use of statins, the difference in heart disease risk between obese and lean adults has become considerably smaller than it once was. Obesity remains a serious health concern, but carrying excess weight no longer carries quite the same additional cardiovascular risk seen in previous generations. That doesn’t mean losing weight isn’t worthwhile – it certainly is, for reasons ranging from joint health to diabetes prevention – but modern preventive medicine has changed the picture.

A changing picture of cardiovascular risk

Body mass index (BMI) has long been used to estimate cardiovascular risk. Large population studies throughout the late twentieth century consistently showed that people classified as obese experienced significantly higher rates of coronary heart disease than those of healthy weight.

The reasons are well understood. Obesity often raises levels of low-density lipoprotein (LDL), the so-called “bad” cholesterol, while lowering protective HDL cholesterol. It also contributes to high blood pressure, diabetes and chronic inflammation, all of which damage blood vessels over time. Together, these factors historically produced much higher rates of heart attack and stroke among obese adults.

Today, however, the picture is more nuanced.

Although obesity still increases cardiovascular risk, recent studies show that the gap between obese and normal-weight adults is often much smaller than it was several decades ago. One of the most likely explanations is the success of preventive cardiovascular medicine, particularly statin therapy.

How statins transformed prevention

Since their introduction in the late 1980s, statins have revolutionised cardiovascular care. They work by blocking an enzyme involved in cholesterol production in the liver, significantly lowering LDL cholesterol in the bloodstream.

Lower LDL levels mean less cholesterol is deposited in artery walls, slowing the development of atherosclerosis – the narrowing and hardening of arteries that ultimately leads to heart attacks and strokes.

Large clinical trials have consistently showed that statins reduce the risk of major cardiovascular events by around 20–25% for each significant reduction in LDL cholesterol. These benefits extend across a wide range of patients, including those with diabetes, hypertension and obesity.

Because obesity is often accompanied by raised cholesterol and other cardiovascular risk factors, obese patients are more likely to qualify for statin treatment. Over the past two decades, millions of higher-risk individuals have therefore received effective cholesterol-lowering therapy long before developing heart disease. Many of the cardiovascular consequences once associated with obesity are now being actively prevented.

Better treatment means a smaller gap

The widespread use of statins has changed the distribution of cardiovascular risk across the population.

Years ago, many obese adults remained untreated despite elevated cholesterol, allowing risk to accumulate over time. Today, routine cholesterol testing, cardiovascular risk calculators and evidence-based prescribing identify high-risk patients much earlier. Many obese adults now begin statin treatment years before symptoms appear.

At the same time, blood pressure is treated more aggressively, diabetes is diagnosed and managed earlier, and smoking rates have declined in many countries. Together, these improvements have substantially reduced the cardiovascular disadvantage associated with obesity.

Researchers describe this as a narrowing of the “risk gap” rather than the elimination of risk. Obese adults still experience higher rates of cardiovascular disease overall, but the excess risk is no longer as large as it once was.

Obesity still matters

None of this means obesity has become harmless.

Statins address only one part of a much more complex health picture. While they are extremely effective at lowering LDL cholesterol, they do not directly treat many of obesity’s other consequences.

Excess weight remains a major contributor to type 2 diabetes, sleep apnoea, fatty liver disease, osteoarthritis, kidney disease, several cancers and reduced mobility. Within cardiovascular medicine, obesity also increases the risk of heart failure and atrial fibrillation through mechanisms that statins cannot fully address.

Weight loss, whether achieved through healthier eating, regular physical activity, behavioural support or newer anti-obesity medications, improves blood pressure, blood sugar control, inflammation and quality of life. These benefits complement statin therapy rather than replace it.

Personalised prevention

Modern cardiovascular prevention increasingly focuses on an individual’s overall risk rather than weight alone.

Doctors now consider combinations of factors including age, blood pressure, cholesterol levels, smoking status, diabetes, family history and kidney function. In some people, special coronary artery calcium scans provide additional information. Together, these measures offer a much more accurate assessment of cardiovascular risk than BMI alone.

This means some people with obesity will benefit greatly from statins because their overall cardiovascular risk is high, while others – particularly younger adults without additional risk factors – may not need medication immediately.

Equally, slim people should not assume they are protected simply because of their weight. Many normal-weight adults have inherited high cholesterol, hypertension, diabetes or unhealthy lifestyles that place them at significant cardiovascular risk despite having a healthy BMI.

Cardiovascular prevention has therefore become increasingly personalised rather than driven by body size alone.

A public health success story

The narrowing of the cardiovascular risk gap between obese and lean adults represents a genuine public health success. It demonstrates how advances in medical treatment can alter the relationship between traditional risk factors and disease.

Statins have prevented countless heart attacks and strokes, particularly among people whose obesity places them at increased cardiovascular risk. Combined with better blood pressure control, improved diabetes care, smoking cessation and earlier preventive intervention, they have helped transform heart disease from an almost inevitable consequence of multiple risk factors into a condition that can often be delayed – or prevented altogether.

Medication, however, works best alongside healthy living. Statins reduce cardiovascular risk, but they do not eliminate it. We are fortunate to live where we do, here on the Costa del Sol, where we can enjoy a nutritious Mediterranean diet. Staying physically active, avoiding tobacco, limiting excessive alcohol and managing weight all continue to provide health benefits that no single medicine can replicate.

The emerging evidence therefore offers both reassurance and perspective. Obesity remains an important health issue, but thanks to decades of progress in cardiovascular medicine, it no longer carries quite the same unavoidable heart disease penalty that it once did. The gap has narrowed – not because obesity has become safer, but because medicine has become much better at protecting those most at risk.

The information provided in this column is for educational and informational purposes only, and does not constitute medical advice. It is not a substitute for a professional medical consultation, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health provider with any questions you may have regarding a medical condition.

Dr Marcus Stephan